| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8746357 | Journal of Global Antimicrobial Resistance | 2017 | 16 Pages |
Abstract
Approved agents available for the treatment of SSSI in children are limited. Dalbavancin demonstrated potent in vitro activity against isolates causing SSSI in children. Developing dalbavancin for SSSI treatment in children is warranted, provided safety and tolerability are satisfactory.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Michael A. Pfaller, Rodrigo E. Mendes, Helio S. Sader, Mariana Castanheira, Robert K. Flamm,